FinCanna Capital Corp. (OTCPK: FNNZ.F)
Health Care · Pharmaceuticals · CA
$0.00
— today · -99.9% 1Y
FinCanna Capital Corp. (OTCPK: FNNZ.F) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $999.00.
Over the last twelve months the share price has lost 99.9%, trading between 0.00 and 0.00.
Tweenvest scores FinCanna Capital Corp. across four factors: quality 12/100, value 42/100. Its strongest factor is value.
FNNZ.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $999.00
- Revenue (TTM)
- $-335.62K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 1.53
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 998.53M
- Employees
- —
- Next earnings
- —
About FinCanna Capital Corp.
FinCanna Capital Corp. operates as an investment company for the licensed cannabis industry in the United States. It provides financing for companies operating in the cannabis sector. The company has royalty agreements with Green Compliance Inc.; and Refined Resin. FinCanna Capital Corp. was incorporated in 2016 is headquartered in Vancouver, Canada.
- ISIN
- CA31773B5018
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,243.03 | -0.99% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.61 | +1.25% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $151.45 | -0.72% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.01 | -0.23% |
Figures last refreshed Aug 18, 2026.